

Nicola Farina

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1268864/publications.pdf>

Version: 2024-02-01

20
papers

1,361
citations

933447

10
h-index

940533

16
g-index

20
all docs

20
docs citations

20
times ranked

3569
citing authors

#	ARTICLE	IF	CITATIONS
1	Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. <i>Lancet Rheumatology</i> , The, 2020, 2, e325-e331.	3.9	808
2	GM-CSF blockade with mavrimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. <i>Lancet Rheumatology</i> , The, 2020, 2, e465-e473.	3.9	173
3	Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e253-e261.	3.9	140
4	Low prevalence of arrhythmias in clinically stable COVID-19 patients. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2020, 43, 891-893.	1.2	43
5	Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series. <i>European Journal of Internal Medicine</i> , 2021, 93, 87-94.	2.2	41
6	Obesity and its role in the management of rheumatoid and psoriatic arthritis. <i>Clinical Rheumatology</i> , 2020, 39, 1039-1047.	2.2	32
7	Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic. <i>Frontiers in Pharmacology</i> , 2020, 11, 598308.	3.5	29
8	COVID-19: Pharmacology and kinetics of viral clearance. <i>Pharmacological Research</i> , 2020, 161, 105114.	7.1	17
9	Current treatment options and safety considerations when treating adult-onset Still's disease. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1549-1558.	2.4	15
10	Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e11-e11.	0.9	15
11	Drug retention rates of biological agents in adult onset Still's disease. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1-6.	3.4	14
12	Impact of the COVID-19 pandemic in patients with systemic lupus erythematosus throughout one year. <i>Clinical Immunology</i> , 2021, 231, 108845.	3.2	14
13	Beyond Neuropsychiatric Manifestations of Systemic Lupus Erythematosus: Focus on Post-traumatic Stress Disorder and Alexithymia. <i>Current Rheumatology Reports</i> , 2021, 23, 52.	4.7	6
14	The Role of the Multidisciplinary Health Care Team in the Management of Patients with Systemic Sclerosis. <i>Journal of Multidisciplinary Healthcare</i> , 2022, Volume 15, 815-824.	2.7	6
15	Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors. <i>European Journal of Internal Medicine</i> , 2022, 103, 95-99.	2.2	6
16	Canakinumab injection for the treatment of active Still's disease, including adult-onset Still's disease. <i>Expert Opinion on Orphan Drugs</i> , 2021, 9, 77-86.	0.8	1
17	Patients' experience and tolerability with canakinumab and anakinra for the treatment of adult-onset Still's disease.. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.8	1
18	Catastrophic antiphospholipid syndrome presenting with aortic barrage: case report and review of the literature. <i>Lupus</i> , 2021, 30, 1005-1009.	1.6	0

#	ARTICLE	IF	CITATIONS
19	Patients' experience and tolerability with canakinumab and anakinra for the treatment of adult-onset Still's disease.. Clinical and Experimental Rheumatology, 2022, , .	0.8	0
20	Interleukin 6 inhibition in severe COVID-19: Another piece of the puzzle. European Journal of Internal Medicine, 2022, , .	2.2	0